Titan Pharmaceuticals Inc. Watch

from 8-K 43 pages 80,000,000 Shares of Common Stock and 80,000,000 Warrants (Exercisable for 80,000,000 Shares) of Titan Pharmaceuticals, Inc. Underwriting Agreement

from S-1 43 pages [ ] Shares of Common Stock and [ ] Warrants (Exercisable for [ ] Shares) of Titan Pharmaceuticals, Inc. Underwriting Agreement

from 8-K 43 pages 35,610,000 Shares of Common Stock, 4,390,000 Pre-Funded Warrants (Exercisable for 4,390,000 Shares) and 40,000,000 Class B Warrants (Exercisable for 40,000,000 Shares) of Titan Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 41 pages [ ] Shares of Common Stock, [ ] Pre-Funded Warrants (Exercisable for [ ] Shares), [ ] Class B Warrants (Exercisable for [ ] Shares), and [ ] Class C Warrants (Exercisable for [ ] Shares) of Titan Pharmaceuticals, Inc. Underwriting Agreement

from S-1 41 pages [ ] Shares of Common Stock, [ ] Pre-Funded Warrants (Exercisable for [ ] Shares) and [ ] Warrants (Exercisable for [ ] Shares) of Titan Pharmaceuticals, Inc. Underwriting Agreement

from 8-K 54 pages Underwriting Agreement Between Titan Pharmaceuticals, Inc. and A.G.P./ALLIANCE Global Partners, as Representative of the Several Underwriters 1 Titan Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 54 pages Underwriting Agreement Between Titan Pharmaceuticals, Inc. and A.G.P./ALLIANCE Global Partners, as Representative of the Several Underwriters Titan Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 34 pages Titan Pharmaceuticals, Inc. · Each Unit Consisting of One Share of Common Stock and 0.75 of a Class a Warrant, Each to Purchase One Share of Common Stock Underwriting Agreement

from 8-K 14 pages Confidential Titan Pharmaceuticals, Inc. 400 Oyster Point Blvd., Suite 505 South San Francisco, Ca 94080 Attn: Sunil Bhonsle, President Dear Mr. Bhonsle

from 8-K 8 pages Confidential November 28, 2007 Titan Pharmaceuticals, Inc. 400 Oyster Point Boulevard Suite 505 South San Francisco, California 94080 Attn: Marc Rubin President and CEO Dear Marc: 1. Services to Be Rendered. in Performing Its Agency and Advisory Roles, Ca and Rodman Will: (A) Familiarize Themselves to the Extent They Deem Appropriate and Feasible With the Business, Operations, Properties, Financial Condition and Prospects of Client; (B) Assist Client in the Development of Descriptive Textual and Financial Materials for Distribution to Potential Investors; (C) Review With Client a List of Potential Investors; and (D) Solicit Offers From Potential Investors, Collaborate With Client in the Development and Proposal of Terms of Any Offers, and Participate In, and Assist Client With, Negotiations in Connection With the Consummation of the Private Placement

from 8-K 10 pages Draft Confidential Louis R. Bucalo, M.D. Chairman, President & Chief Executive Officer Titan Pharmaceuticals, Inc. 400 Oyster Point Blvd., Suite 505 South San Francisco, Ca 94080 Dear Dr. Bucalo

from 8-K 1 page (A) a Cash Fee Payable Immediately Upon the Closing of Any Portion of Any Financing (Including Without Limitation the Offering) and Equal to 6% of the Aggregate Proceeds Raised. (B) Up to $15,000 Expense Allowance for Incurred Expenses

from 8-K 2 pages Exhibit 1.1

from 10QSB ~20 pages Titan Exhibit 10.19